The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT). MSK’s Anas Younes is quoted.